FibroGen(US:FGEN)2023-03-10 13:50Pamrevlumab Development - Pamrevlumab is a unique Phase 3 investigational drug with potential disease-modifying mechanism across fibrotic diseases[14,18] - Phase 3 data is being delivered in three high-value indications: Idiopathic pulmonary fibrosis (IPF), Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer (LAPC)[7] - PRAISE Phase 2 study in IPF showed a 4.33% FVC%-Predicted Difference and a 60% relative difference between pamrevlumab and placebo[25] - In Locally Advanced Pancreatic Cancer, patients with Pamrevlumab Day 15 C min ≥median (150 μg/mL) had a median OS of 9.0 months and a 1-Year OS Rate of 34.2%, compared to 4.4 months and 10.8% for those <median (150 μg/mL)[46] Roxadustat Update - Roxadustat is a novel, first-in-class treatment for CKD anemia, leveraging the body's natural response to hypoxia[10,87] - Roxadustat net sales to distributors in China were $53.1 million in Q4 2022, compared to $32.0 million a year ago, driven by a volume increase of over 90%[102,97] - Roxadustat China unit volume was up 78% in 2022 compared to the same period last year[103,105] Pipeline and Financial Status - The company advanced its pipeline and delivered on its clinical trial goals by completing enrollment of six pamrevlumab and roxadustat pivotal trials[3] - The company has a strong financial position with $442.7 million in cash as of December 31, 2022, and continues to remain focused on financial discipline[4,123]